Clinical trial · Observational
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
A Cross-Sectional Patient-Reported Study To Assess The Patient Preference Of Treatment Administration Setting, Impact On Health-Related Quality Of Life, Work Productivity, Wider Societal Costs And Healthcare Utilisation For Patients With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Prescribed Somatuline® Autogel® In A Homecare Setting and Hospital Setting.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumours (NET) | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Online Survey
- label
- One-to-one interviews
Primary outcomes (1)
- measure
- Patient preferences of treatment administration setting (homecare or hospital)
- timeFrame
- Baseline
- description
- Survey responses of patient experience of injections at home and compared to responses of patient experience of injections when given in hospital
Secondary outcomes (8)
- measure
- Demographic characteristics of enrolled patients with GEP-NETs
- timeFrame
- Baseline
- description
- Age (years); Gender (male, female); Current employment status: full time, part time, unemployed, retired, student, homemaker, unpaid carer)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of GEP-NETs * Patients on prescribed lanreotide Autogel®; * Patients who have switched from hospital to homecare administration setting at least 2 months ago * Patients judged to be on a stable dose; 120mg for tumour control or \>1 injection at same dose for symptom control Exclusion Criteria: * Patients who decline or lack capacity to consent to participate in the study
References
Publications (0)
Data not yet available